Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 5,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Cancer Clear all
Recruiting Phase 1 Interventional

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

NCT07080242
View directory record Official record
Conditions
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
BL-M14D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Huntsville, Alabama • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Active, not recruiting Phase 1 Interventional

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

NCT03220477
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab, Guadecitabine, Mocetinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Completed Not applicable Interventional Results available

The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale

NCT06338592
View directory record Official record
Conditions
Lung Cancer, Lung Neoplasms/Diagnosis
Interventions
MyLungHealth, DecisionPrecision+
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 79 Years
Enrollment
31,303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Terminated Phase 1 Interventional

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06560645
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
PRT7732
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Terminated No phase listed Observational

Surveillance For New Lung Primaries

NCT00205439
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 13, 2026, 6:29 AM EST
Terminated No phase listed Observational Results available

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer

NCT02762877
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Genomic Health®, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Torrance, California • Macon, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 13, 2026, 6:29 AM EST
Recruiting Phase 2 Interventional

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Rina-S
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Fountain Valley, California • Irvine, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Recruiting No phase listed Observational

Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer

NCT04063501
View directory record Official record
Conditions
Lung Cancer
Interventions
Bronchoscopy, Research Procedures
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Active, not recruiting Phase 3 Interventional

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266
View directory record Official record
Conditions
NSCLC
Interventions
Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Completed Phase 1 Interventional

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

NCT00020007
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
isolated perfusion, paclitaxel, hyperthermia treatment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Nov 13, 2026, 6:29 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

NCT05887492
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Interventions
TNG260, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Santa Monica, California • Denver, Colorado • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Terminated Phase 1 Interventional

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05757492
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Nov 13, 2026, 6:29 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Yoga Program for Improving the Quality of Life in Couples Coping With Cancer

NCT04607590
View directory record Official record
Conditions
Esophageal Carcinoma, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Nov 13, 2026, 6:29 AM EST
Recruiting Phase 1 Interventional

Study of XB010 in Subjects With Solid Tumors

NCT06545331
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
XB010, Pembrolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Terminated Phase 2 Interventional Results available

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

NCT00520845
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, Docetaxel, pemetrexed disodium, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 13, 2026, 6:29 AM EST
Recruiting Phase 1Phase 2 Interventional

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Interventions
STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D), STX-721/PFL-721 (Escalated) with platinum-based chemotherapy, STX-721/PFL-721 with platinum-based chemotherapy
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Withdrawn Phase 4 Interventional

Genetically-informed Therapies for Patients With Metastatic Cancer

NCT02000739
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Genetically Informed Therapy
Genetic
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Nov 13, 2026, 6:29 AM EST
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 13, 2026, 6:29 AM EST
Completed Phase 2 Interventional Results available

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

NCT00309907
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
etanercept, methylprednisolone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Nov 13, 2026, 6:29 AM EST
Recruiting No phase listed Observational

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

NCT07339254
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 13, 2026, 6:29 AM EST
Completed No phase listed Observational

Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status

NCT05634551
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Questionnaires, Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Nov 13, 2026, 6:29 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2

NCT00158145
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
55 Years to 74 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Nov 13, 2026, 6:29 AM EST
Completed Not applicable Interventional Results available

Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC

NCT02440139
View directory record Official record
Conditions
Lung Cancer
Interventions
ClearRead CT Insight
Device
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
55 Years to 77 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 13, 2026, 6:29 AM EST